<i>Candida vulturna</i> Outbreak Caused by Cluster of Multidrug-Resistant Strains, China

Du, Han; Jian, Bing; Xiao-hong, XU; Zheng, Qiushi; Hu, Tianren; Hao, Yanpeng; Li, Shuping; Nobile, Clarissa J.; Zhan, Ping; Huang, Guanghua

doi:10.3201/eid2907.230254

Cited by 6 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This fungus is phylogenetically related to Candida auris, which poses a serious global threat and belongs to the Candida haemulonii species complex of the Metschnikowiaceae family. Human cases of C. vulturna have not been widely reported, and the epidemiology, diagnostic methods, and treatment strategies remain unclear [ [1] , [2] , [3] , [4] , [5] , [6] ]. Herein, we report a case of persistent fungemia in a 67-year-old man caused by C. vulturna that was resistant to antifungal agents.…”

Section: Introductionmentioning

confidence: 99%

“…Known risks for candidemia include the long-term use of antimicrobial agents, immunosuppressive drugs, malignancies, central venous catheters, and gastrointestinal surgery [ 12 ]. The use of peripherally inserted central catheter lines, trauma, hypertension, cancer, as well as blood and lung infections may also be implicated in the development of C. vulturna infections [ 3 ]. The C. haemulonii species complex is known to cause catheter-related bloodstream infections by forming biofilms, similar to C. vulturna [ 3 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

“…The use of peripherally inserted central catheter lines, trauma, hypertension, cancer, as well as blood and lung infections may also be implicated in the development of C. vulturna infections [ 3 ]. The C. haemulonii species complex is known to cause catheter-related bloodstream infections by forming biofilms, similar to C. vulturna [ 3 , 13 ]. In this case, the patient did not have a central venous catheter during his hospitalization; therefore, the placement of a peripheral intravascular catheter without apparent signs of infection, prolonged use of broad-spectrum antimicrobials, and gastrointestinal surgery with postoperative suture failure may have led to C. vulturna fungemia.…”

Section: Introductionmentioning

confidence: 99%

“…Clinical breakpoints based on CLSI are not available for C. vulturna , but previous reports have shown high MICs for azole antifungals and amphotericin B (AMPH-B), as well as low MICs for echinocandin antifungals [ 3 , 6 ]. However, the C. vulturna detected in this case showed high MICs against azole antifungals, but relatively low MICs against AMPH-B ( Table 1 ).…”

Section: Introductionmentioning

confidence: 99%

“…Prior to this case, there were no reports of infections caused by C. haemulonii species complex at our hospital. Furthermore, outbreaks of C. vulturna have only been reported at a single facility in China [ 3 ]. C. vulturna cases were not detected by environmental screening, but a significant decrease in infection rates was observed during the COVID-19 pandemic period, indicating that enhanced disinfection methods may help to prevent the transmission of C. vulturna [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Case report and literature review of refractory fungemia caused by Candida vulturna

Setoguchi,

Iwanaga,

Ito

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Case report and literature review of refractory fungemia caused by Candida vulturna

Setoguchi,

Iwanaga,

Ito

et al. 2024

Heliyon

View full text Add to dashboard Cite

The yeast genus Tardiomyces gen. nov. with one new species and two new combinations

Spruijtenburg,

de Souza Lima,

Tosar

et al. 2024

Infection

View full text Add to dashboard Cite

Purpose Rare yeasts species are increasingly reported as causative agents of invasive human infection. Proper identification and antifungal therapy are essential to manage these infections. Candida blankii is one of these emerging pathogens and is known for its reduced susceptibility to multiple antifungals. Methods To obtain more insight into the characteristics of this species, 26 isolates reported as C. blankii were investigated using genetic and phenotypical approaches. Results Among the 26 isolates, seven recovered either from blood, sputum, urine, or the oral cavity, displayed substantial genetic and some phenotypical differences compared to the other isolates, which were confirmed as C. blankii. We consider these seven strains to represent a novel species, Tardiomyces depauwii. Phylogenomics assigned C. blankii, C. digboiensis, and the novel species in a distinct branch within the order Dipodascales, for which the novel genus Tardiomyces is erected. The new combinations Tardiomyces blankii and Tardiomyces digboiensis are introduced. Differences with related, strictly environmental genera Sugiyamaella, Crinitomyces, and Diddensiella are enumerated. All three Tardiomyces species share the rare ability to grow up to 42 °C, display slower growth in nutrient-poor media, and show a reduced susceptibility to azoles and echinocandins. Characteristics of T. depauwii include high MIC values with voriconazole and a unique protein pattern. Conclusion We propose the novel yeast species Tardiomyces depauwii and the transfer of C. blankii and C. digboiensis to the novel Tardiomyces genus.

show abstract

Artemisinins inhibit oral candidiasis caused by Candida albicans through the repression on its hyphal development

Liang,

Chen,

Wang

et al. 2023

Int J Oral Sci

View full text Add to dashboard Cite

Candida albicans is the most abundant fungal species in oral cavity. As a smart opportunistic pathogen, it increases the virulence by switching its forms from yeasts to hyphae and becomes the major pathogenic agent for oral candidiasis. However, the overuse of current clinical antifungals and lack of new types of drugs highlight the challenges in the antifungal treatments because of the drug resistance and side effects. Anti-virulence strategy is proved as a practical way to develop new types of anti-infective drugs. Here, seven artemisinins, including artemisinin, dihydroartemisinin, artemisinic acid, dihydroartemisinic acid, artesunate, artemether and arteether, were employed to target at the hyphal development, the most important virulence factor of C. albicans. Artemisinins failed to affect the growth, but significantly inhibited the hyphal development of C. albicans, including the clinical azole resistant isolates, and reduced their damage to oral epithelial cells, while arteether showed the strongest activities. The transcriptome suggested that arteether could affect the energy metabolism of C. albicans. Seven artemisinins were then proved to significantly inhibit the productions of ATP and cAMP, while reduced the hyphal inhibition on RAS1 overexpression strain indicating that artemisinins regulated the Ras1-cAMP-Efg1 pathway to inhibit the hyphal development. Importantly, arteether significantly inhibited the fungal burden and infections with no systemic toxicity in the murine oropharyngeal candidiasis models in vivo caused by both fluconazole sensitive and resistant strains. Our results for the first time indicated that artemisinins can be potential antifungal compounds against C. albicans infections by targeting at its hyphal development.

show abstract

Candida vulturna Outbreak Caused by Cluster of Multidrug-Resistant Strains, China

Cited by 6 publications

References 14 publications

Case report and literature review of refractory fungemia caused by Candida vulturna

Case report and literature review of refractory fungemia caused by Candida vulturna

The yeast genus Tardiomyces gen. nov. with one new species and two new combinations

Artemisinins inhibit oral candidiasis caused by Candida albicans through the repression on its hyphal development

Contact Info

Product

Resources

About